Published in Oncology (Williston Park) on August 01, 2012
Origins of metastatic traits. Cancer Cell (2013) 2.49
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol (2016) 1.54
Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. PLoS One (2014) 1.17
Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res (2013) 1.15
Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene (2013) 0.95
MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention. Cancer Lett (2013) 0.95
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat (2014) 0.90
Anti-cancer potential of a novel SERM ormeloxifene. Curr Med Chem (2013) 0.89
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget (2017) 0.87
Dietary γ-Tocopherol-Rich Mixture Inhibits Estrogen-Induced Mammary Tumorigenesis by Modulating Estrogen Metabolism, Antioxidant Response, and PPARγ. Cancer Prev Res (Phila) (2015) 0.83
Soy and breast cancer: focus on angiogenesis. Int J Mol Sci (2015) 0.82
Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen. Oncol Lett (2013) 0.82
Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells. Sci Rep (2016) 0.81
Tocopherols inhibit oxidative and nitrosative stress in estrogen-induced early mammary hyperplasia in ACI rats. Mol Carcinog (2014) 0.81
The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. Clin Epigenetics (2015) 0.81
Metastasis: an early event in cancer progression. J Cancer Res Clin Oncol (2016) 0.81
Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence. Front Oncol (2016) 0.78
Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α. Mol Endocrinol (2014) 0.77
Sonochemotherapy of breast adenocarcinoma: an experimental in vivo model. J Ultrasound (2014) 0.75
Patterns in target-directed breast cancer research. Springerplus (2016) 0.75
Hormone receptor-positive breast cancer: the known and the unknown. Oncology (Williston Park) (2012) 0.75
The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing concept. Oncology (Williston Park) (2012) 0.75
Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study. Oncotarget (2017) 0.75
A preliminary study of (18)F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. Sci Rep (2017) 0.75
TRAIL DR5-CTSB crosstalk participates in breast cancer autophagy initiated by SAHA. Cell Death Discov (2017) 0.75
The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
CNS metastases in breast cancer. J Clin Oncol (2004) 4.42
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol (2004) 4.03
Informing clinical trial participants about study results. JAMA (2002) 3.76
Local therapy and survival in breast cancer. N Engl J Med (2007) 3.33
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol (2008) 3.04
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res (2009) 2.90
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer (2008) 2.82
Brain metastases: the HER2 paradigm. Clin Cancer Res (2007) 2.81
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst (2009) 2.77
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med (2013) 2.76
The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer (2010) 2.63
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol (2013) 2.35
Do patients participating in clinical trials want to know study results? J Natl Cancer Inst (2003) 2.33
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 2.32
American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol (2011) 2.30
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst (2010) 2.28
Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol (2006) 2.24
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw (2006) 2.15
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol (2005) 2.09
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol (2012) 2.07
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
Offering participants results of a clinical trial: sharing results of a negative study. Lancet (2005) 1.90
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw (2006) 1.88
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol (2007) 1.85
Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol (2007) 1.77
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev (2013) 1.73
Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol (2011) 1.72
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol (2008) 1.69
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol (2012) 1.62
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol (2013) 1.62
Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat (2003) 1.60
Complementary and alternative medicine use among women with breast cancer. J Clin Oncol (2002) 1.60
Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res (2010) 1.56
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2009) 1.53
Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery? Med Care (2009) 1.51
Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst (2004) 1.51
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res (2012) 1.50
Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health (2008) 1.48
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer (2007) 1.47
Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer (2008) 1.45
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat (2012) 1.43
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol (2002) 1.42
Body image in recently diagnosed young women with early breast cancer. Psychooncology (2012) 1.36
The association of ambulatory care with breast cancer stage at diagnosis among Medicare beneficiaries. J Gen Intern Med (2005) 1.35
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat (2008) 1.32
Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. J Clin Oncol (2003) 1.31
Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol (2008) 1.28
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res (2008) 1.27
Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast (2013) 1.23
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res (2012) 1.22
Sharing study results with trial participants: time for action. J Clin Oncol (2009) 1.22
Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol (2007) 1.19
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol (2011) 1.17
On mammography--more agreement than disagreement. N Engl J Med (2009) 1.17
The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. J Clin Oncol (2012) 1.16
The effect of age on delay in diagnosis and stage of breast cancer. Oncologist (2012) 1.15
Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer (2008) 1.13
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat (2008) 1.12
Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women. Breast Cancer Res Treat (2009) 1.11
The ethical use of mandatory research biopsies. Nat Rev Clin Oncol (2011) 1.11
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol (2004) 1.10
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer (2008) 1.10
Sarcoidosis mimicking metastatic breast cancer. Clin Breast Cancer (2007) 1.10
Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health (2007) 1.06
Effect of Massachusetts health insurance reform on mammography use and breast cancer stage at diagnosis. Cancer (2012) 1.05
Model program to improve care for a unique cancer population: young women with breast cancer. J Oncol Pract (2012) 1.05
Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test (2002) 1.04
Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis (2010) 1.04